Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC3014990670;90671;90672 chr2:178552455;178552454;178552453chr2:179417182;179417181;179417180
N2AB2850885747;85748;85749 chr2:178552455;178552454;178552453chr2:179417182;179417181;179417180
N2A2758182966;82967;82968 chr2:178552455;178552454;178552453chr2:179417182;179417181;179417180
N2B2108463475;63476;63477 chr2:178552455;178552454;178552453chr2:179417182;179417181;179417180
Novex-12120963850;63851;63852 chr2:178552455;178552454;178552453chr2:179417182;179417181;179417180
Novex-22127664051;64052;64053 chr2:178552455;178552454;178552453chr2:179417182;179417181;179417180
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: V
  • RefSeq wild type transcript codon: GTG
  • RefSeq wild type template codon: CAC
  • Domain: Ig-148
  • Domain position: 18
  • Structural Position: 28
  • Q(SASA): 0.2205
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
V/M rs1699816128 None 0.901 N 0.665 0.262 0.388010793773 gnomAD-4.0.0 1.60543E-06 None None None None N None 0 0 None 0 0 None 0 0 0 0 3.04822E-05

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
V/A 0.4739 ambiguous 0.4561 ambiguous -1.622 Destabilizing 0.517 D 0.585 neutral N 0.452920239 None None N
V/C 0.7819 likely_pathogenic 0.7667 pathogenic -1.188 Destabilizing 0.996 D 0.714 prob.delet. None None None None N
V/D 0.9612 likely_pathogenic 0.9615 pathogenic -1.317 Destabilizing 0.987 D 0.792 deleterious None None None None N
V/E 0.9262 likely_pathogenic 0.9316 pathogenic -1.236 Destabilizing 0.983 D 0.745 deleterious N 0.499821251 None None N
V/F 0.2745 likely_benign 0.3114 benign -1.067 Destabilizing 0.923 D 0.755 deleterious None None None None N
V/G 0.6777 likely_pathogenic 0.6646 pathogenic -2.036 Highly Destabilizing 0.949 D 0.765 deleterious N 0.499821251 None None N
V/H 0.9553 likely_pathogenic 0.9613 pathogenic -1.549 Destabilizing 0.996 D 0.759 deleterious None None None None N
V/I 0.0721 likely_benign 0.078 benign -0.549 Destabilizing 0.005 N 0.227 neutral None None None None N
V/K 0.9421 likely_pathogenic 0.9486 pathogenic -1.357 Destabilizing 0.961 D 0.739 prob.delet. None None None None N
V/L 0.1663 likely_benign 0.2284 benign -0.549 Destabilizing 0.003 N 0.202 neutral N 0.450765369 None None N
V/M 0.2056 likely_benign 0.2302 benign -0.478 Destabilizing 0.901 D 0.665 neutral N 0.488211456 None None N
V/N 0.8956 likely_pathogenic 0.9002 pathogenic -1.295 Destabilizing 0.987 D 0.795 deleterious None None None None N
V/P 0.9735 likely_pathogenic 0.9756 pathogenic -0.872 Destabilizing 0.987 D 0.755 deleterious None None None None N
V/Q 0.9043 likely_pathogenic 0.9085 pathogenic -1.323 Destabilizing 0.987 D 0.756 deleterious None None None None N
V/R 0.9142 likely_pathogenic 0.9162 pathogenic -0.968 Destabilizing 0.961 D 0.795 deleterious None None None None N
V/S 0.7594 likely_pathogenic 0.7358 pathogenic -1.936 Destabilizing 0.961 D 0.741 deleterious None None None None N
V/T 0.5545 ambiguous 0.5555 ambiguous -1.717 Destabilizing 0.775 D 0.62 neutral None None None None N
V/W 0.9438 likely_pathogenic 0.9565 pathogenic -1.336 Destabilizing 0.996 D 0.761 deleterious None None None None N
V/Y 0.8256 likely_pathogenic 0.8391 pathogenic -1.01 Destabilizing 0.961 D 0.768 deleterious None None None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.